Myeloid malignancies are characterized by excessive proliferation, abnormal self-renewal, and differentiation defects of hematopoietic stem cells and myeloid progenitor cells. The detection of these types of malignancies using traditional procedures by obtaining bone marrow samples is invasive and risky. Hence, liquid biopsy-based methods are in high demand to monitor and detect new cases of blood cancer.
This poster from LGC SeraCare summarizes the development of ctDNA myeloid reference materials — a purified mix of 25 myeloid DNA variants that were blended against a wild-type background — for the development, validation, and clinical application of targeted NGS assays as well as digital PCR-based assays that analyze for myeloid diseases in cancer patients.
Offered Free by: LGC SeraCare Life Sciences
See All Resources from: LGC SeraCare Life Sciences